HIV Infections Clinical Trial
Official title:
A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/ Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents
Verified date | July 2018 |
Source | Gilead Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objectives of this study are to evaluate the steady-state pharmacokinetics (PK)
and confirm the dose of the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil
fumarate (EVG/COBI/FTC/TDF) single-tablet regimen (STR) (Part A) and to evaluate the safety
and tolerability of EVG/COBI/FTC/TDF STR through Week 48 (Part B) in HIV-1 infected,
antiretroviral (ARV) treatment-naive adolescents.
A total of 50 adolescent participants (12 to < 18 years of age) will be enrolled to receive
EVG/COBI/FTC/TDF as follows:
- Part A: Twelve to 16 eligible participants will be enrolled to evaluate steady-state PK,
and confirm the dose, with the intent to enroll at least 4 participants 12 to < 15 and
at least 4 participants 15 to < 18 years of age.
- Part B: Following confirmation of EVG exposure in at least 12 participants from Part A,
34 to 38 participants in addition to those enrolled in Part A will be enrolled to
evaluate the safety, tolerability, and antiviral activity of EVG/COBI/FTC/TDF STR.
Status | Completed |
Enrollment | 50 |
Est. completion date | January 29, 2018 |
Est. primary completion date | October 22, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 17 Years |
Eligibility |
Key Inclusion Criteria: - 12 years to < 18 years of age at baseline - Able to give written assent prior to any screening evaluations - Parent or guardian able to give written informed consent prior to any screening evaluations and willing to comply with study requirements - Plasma HIV-1 RNA levels of = 1,000 copies/mL - CD4+ cell count > 100 cells/µL - Weight = 35 kg (77 lbs) - Screening genotype report must show sensitivity to FTC and TDF - Able to swallow oral tablets - Adequate renal function - Clinically normal ECG - Documented screening for active pulmonary tuberculosis per local standard of care within 6 months of a screening visit - Hepatic transaminases = 5 x upper limit of normal - Total bilirubin = 1.5 mg/dL, or normal direct bilirubin - Individuals with a positive Hepatitis B surface antigen screening test can participate in the study, providing that alternate therapy (other than TDF) for chronic Hepatitis B infection is available as a part of local standard of care - Adequate hematologic function - Negative serum pregnancy test for all females - Males and females of childbearing potential must agree to utilize highly effective contraception methods while on study treatment or agree to abstain from heterosexual intercourse throughout the study period and for 30 days following the last dose of study drug - Males must agree to utilize a highly effective method of contraception during heterosexual intercourse throughout the study period and for 30 days following discontinuation of investigational medicinal product - Must be willing and able to comply with all study requirements - Life expectancy = 1 year Key Exclusion Criteria: - A new AIDS-defining condition diagnosed within the 30 days prior to screening - Prior treatment with any approved or investigational or experimental anti HIV-1 drug for any length of time (other than that given for prevention of mother-to-child transmission) - Evidence of active pulmonary or extra-pulmonary tuberculosis disease within 3 months of the screening visit - Anticipated to require rifamycin treatment for mycobacterial infection while participating in the study. Note: prophylactic Isoniazid (INH) therapy for latent tuberculosis (TB) treatment is allowed. - Individuals experiencing decompensated cirrhosis - Pregnant or lactating females - Have any serious or active medical or psychiatric illness which would interfere with treatment, assessment, or compliance with the protocol. This would include uncontrolled renal, cardiac, hematological, hepatic, pulmonary, endocrine, central nervous, gastrointestinal, vascular, metabolic, immunodeficiency disorders, active infection, or malignancy that are clinically significant or requiring treatment within 30 days prior to the study dosing. - Current alcohol or substance abuse that will potentially interfere with compliance - Have history of significant drug sensitivity or drug allergy - Known hypersensitivity to the study drugs, the metabolites or formulation excipients - Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3 months of study screening or expected to receive these agents during the study - A history of malignancy within the past 5 years or ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non-invasive cutaneous squamous carcinoma - Have previously participated in an investigational trial involving administration of any investigational agent within 30 days prior to the study dosing - Participation in any other clinical trial without prior approval from sponsor is prohibited while participating in this trial - Receiving ongoing therapy with any disallowed medications, including drugs not to be used with EVG, COBI, FTC, TDF or individuals with any known allergies to the excipients of EVG/COBI/FTC/TDF STR tablets Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
South Africa | Desmond Tutu HIV Research Centre | Cape Town | |
South Africa | Mpati Medical Center | Dundee | |
South Africa | Dr Latiff Private Practice | Durban | Kwazulu-Natal |
South Africa | Clinical HIV Research Unit | Johannesburg | |
South Africa | Rahima Moosa Mother and Child Hospital (Wits) | Johannesburg | Gauteng |
South Africa | Perinatal HIV Research Unit | Soweto | |
South Africa | University of Stellenbosch | Stellenbosch | |
Thailand | Siriraj Hospital, Mahidol University | Bangkok | |
Thailand | The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT) | Bangkok | |
Thailand | Queen Savang Vadhana Memorial Hospital | Chon Buri | |
Thailand | Srinakarind Hospital | Khon Kaen | |
United States | Montefiore Medical Center | Bronx | New York |
United States | University of Chicago | Chicago | Illinois |
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | New York University School of Medicine | New York | New York |
United States | East Bay AIDS Center Medical Group | Oakland | California |
United States | St. Christopher's Hospital for Children | Philadelphia | Pennsylvania |
United States | University of South Florida - Department of Pediatrics | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Gilead Sciences |
United States, South Africa, Thailand,
Chokephaibulkit K, Gaur A, Fourie J, Bekker L-G, Shao Y, Custodio J, Bennett S, Cheng A, Quirk E. Safety and Efficacy of the Integrase Inhibitor-Based Stribild Single-Tablet Regimen in HIV-Infected Adolescents Through 24 Weeks of Treatment. 20th Internati
Gaur A, Fourie J, Chokephaibulkit K, Bekker L-G, Yin X, Custodio J, Bennett S, Cheng A, Quirk E. Pharmacokinetics, Efficacy and Safety of an Integrase Inhibitor-Based Single-Tablet Regimen in HIV-Infected Treatment-Naïve Adolescents. 21st Conference on Re
Kizito H, Gaur A, Prasitsuebsai W, Rakhmanina N, Chokephaibulkit K, Fourie J, Bekker LG, Shao Y, Bennett S, Quirk E. Changes in renal laboratory markers and bone mineral density in treatment-naïve HIV-1-infected adolescents initiating INSTI-based single-t
Porter DP, Bennett S, Quirk E, Miller MD, White KL. Lack of Emergent Resistance in HIV-1-Infected Adolescents on Elvitegravir-Based STRs. 22nd Conference on Retroviruses and Opportunistic Infections (CROI). February 2015. Seattle, WA, USA
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | For Part A, Pharmacokinetic (PK) Parameter: AUCtau of EVG | AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). | Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10 | |
Primary | Incidence of Treatment-Emergent Serious Adverse Events (SAEs) and All Treatment-Emergent Adverse Events (AEs) | Up to Week 48 plus 30 days | ||
Secondary | For Part A, PK Parameter: Ctau of EVG, FTC, Tenofovir (TFV), and COBI | Ctau is defined as the observed drug concentration at the end of the dosing interval. | Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10 | |
Secondary | For Part A, PK Parameter: Cmax of EVG, FTC, TFV, and COBI | Cmax is defined as the maximum concentration of drug. | Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10 | |
Secondary | For Part A, PK Parameter: AUCtau of FTC, TFV, and COBI | AUCtau is defined as concentration of drug over time (the area under the concentration verses time curve over the dosing interval). | Predose, 2, 4, 4.5, 5, 8, and 12 hours postdose on Day 10 | |
Secondary | Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Weeks 24 and 48 as Defined by the FDA Snapshot Analysis | Weeks 24 and 48 | ||
Secondary | Percentage of Participants With HIV-1 RNA < 400 Copies/mL at Weeks 24 and 48 as Defined by the FDA Snapshot Analysis | Weeks 24 and 48 | ||
Secondary | Change From Baseline in Plasma log10 HIV-1 RNA at Weeks 24 and 48 | Baseline; Weeks 24 and 48 | ||
Secondary | Change From Baseline in CD4+ Cell Count at Weeks 24 and 48 | Baseline; Weeks 24 and 48 | ||
Secondary | Change From Baseline in CD4 Percentage at Weeks 24 and 48 | Baseline; Weeks 24 and 48 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |